Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the stock...
MarketBeat·2d ago
More News
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 20.9% in March
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling...
MarketBeat·4d ago
Piper Sandler Reaffirms "Overweight" Rating for Karyopharm Therapeutics (NASDAQ:KPTI)
Piper Sandler reiterated an "overweight" rating and set a $8.00 target price (down from $12.00) on shares of Karyopharm Therapeutics in a research note on Monday...
MarketBeat·6d ago
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·9d ago
HC Wainwright Has Optimistic Outlook of KPTI Q1 Earnings
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Analysts at HC Wainwright boosted their Q1 2026 EPS estimates for Karyopharm Therapeutics in a note issued to investors on Wednesday, March...
MarketBeat·9d ago
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.
Zacks·11d ago
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $15.00 at Robert W. Baird
Robert W. Baird reduced their price target on Karyopharm Therapeutics from $21.00 to $15.00 and set an "outperform" rating for the company in a report on Wednesday...
MarketBeat·11d ago
Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?
Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks·11d ago
HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $8.00
HC Wainwright decreased their price objective on Karyopharm Therapeutics from $15.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday...
MarketBeat·11d ago
Nuclear Stocks Worth Watching - March 24th
Oklo, NuScale Power, Karyopharm Therapeutics, BWX Technologies, and Centrus Energy are the five Nuclear stocks to watch today, according to MarketBeat's stock screener tool. "Nuclear stocks" are...